| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Anastrozole,
Ribociclib
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Ribociclib
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Ribociclib
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
HER2-positive
|
Invasive Breast Carcinoma |
Anastrozole,
Trastuzumab
|
|
| Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Anastrozole,
Trastuzumab
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
HER2-positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
HER2-positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Trastuzumab
|
|
| Sensitivity (+) |
ER positive,
HER2-positive
|
Invasive Breast Carcinoma |
Anastrozole,
Trastuzumab
|
|
| Sensitivity (+) |
HER2-positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Trastuzumab
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Abemaciclib,
Anastrozole
|
|
| Sensitivity (+) |
ER positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole,
Goserelin,
Ribociclib
|
|
| Sensitivity (+) |
ER positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|
| Sensitivity (+) |
ER positive,
PR positive
|
Invasive Breast Carcinoma |
Anastrozole
|
|